Sanctuary Advisors LLC Purchases 1,017 Shares of Stryker Co. (NYSE:SYK)

Sanctuary Advisors LLC grew its stake in Stryker Co. (NYSE:SYK - Free Report) by 1.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 66,596 shares of the medical technology company's stock after acquiring an additional 1,017 shares during the quarter. Sanctuary Advisors LLC's holdings in Stryker were worth $26,001,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Dunhill Financial LLC grew its position in shares of Stryker by 94.9% in the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company's stock valued at $27,000 after purchasing an additional 37 shares during the period. Darwin Wealth Management LLC acquired a new position in shares of Stryker in the 3rd quarter valued at approximately $36,000. Activest Wealth Management acquired a new position in shares of Stryker in the 4th quarter valued at approximately $36,000. Crews Bank & Trust acquired a new position in shares of Stryker in the 4th quarter valued at approximately $39,000. Finally, Hara Capital LLC acquired a new position in shares of Stryker in the 3rd quarter valued at approximately $42,000. 77.09% of the stock is owned by institutional investors.

Stryker Stock Down 1.0 %

Shares of Stryker stock traded down $3.82 on Friday, reaching $382.59. 1,268,413 shares of the company were exchanged, compared to its average volume of 1,388,856. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The company has a market capitalization of $145.99 billion, a price-to-earnings ratio of 49.30, a PEG ratio of 2.93 and a beta of 0.96. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The company has a 50-day moving average of $378.07 and a 200 day moving average of $368.67.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the previous year, the company posted $3.46 EPS. On average, equities research analysts forecast that Stryker Co. will post 13.49 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.88%. The ex-dividend date of this dividend is Monday, March 31st. Stryker's dividend payout ratio (DPR) is presently 43.30%.

Analyst Upgrades and Downgrades

SYK has been the subject of several research analyst reports. Royal Bank of Canada boosted their price objective on Stryker from $425.00 to $435.00 and gave the company an "outperform" rating in a research report on Wednesday, January 29th. JPMorgan Chase & Co. boosted their price objective on Stryker from $420.00 to $445.00 and gave the company an "overweight" rating in a research report on Wednesday, January 29th. Piper Sandler reiterated an "overweight" rating and issued a $420.00 price objective (up from $380.00) on shares of Stryker in a research report on Wednesday, October 30th. The Goldman Sachs Group upped their price target on Stryker from $384.00 to $427.00 and gave the stock a "neutral" rating in a research report on Thursday, January 30th. Finally, Evercore ISI upped their price target on Stryker from $380.00 to $384.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 30th. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, Stryker has a consensus rating of "Moderate Buy" and an average price target of $420.68.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares in the company, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by company insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.